Stockreport

Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Sionna Therapeutics, Inc.  (SION) 
PDF Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful be [Read more]